The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Watch and wait: defining the indolent patient group in MCL
While mantle cell lymphoma (MCL) can be an aggressive disease, there is a subgroup of patients whose disease poses low risk, thus treatment may not be required. Here, Simon Rule, MD, from Plymouth University, Plymouth, UK, discusses this ‘indolent’ patient group at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX. Prof. Rule explains the difficulties associated with defining this particular patient group, since there are no known baseline biological characteristics of indolent MCL. Prof. Rule also speaks about a large UK-based trial which aims to identify such baseline characteristics by closely monitoring newly diagnosed patients with MCL.
